Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension

Lexaria Bioscience Corp.

Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.
AnodGen will pay royalties on revenues from sales of DehydraTECH-infused powders.
Pre-IND meeting request filed with FDA for DehydraTECH-CBD for hypertension; target date July 30, 2022.
IND-enabling development ongoing; Lexaria expects to submit IND in late 2022 or early 2023.
HYPER-H21-4 study collects 24-hour BP, arterial stiffness, ECG, MRI, biomarkers, and other data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.